AMRX

MKT CAP:$4B

Amneal Pharmaceuticals, Inc.

Market Cap

$4B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$13.26+$0.60 (+4.74%)

Apr 20, 2026

Company Details

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates thro...

CEO

Chirag K. Patel

IPO Date

May 7, 2018

Website

www.amneal.com

Key Metrics TTM

Revenue

$2.4B

+12.5% YoY

Net Income

-$3M

EPS (Diluted)

-$0.08

Free Cash Flow

$136M

Revenue / Share

$7.38

Gross Margin

35.4%

Operating Margin

8.5%

Net Margin

-0.1%

FCF Margin

5.8%

P/S

1.7x

P/E

—

Earnings Reports

Q3 2024

May 1, 2026

PENDING

FY 2025

Feb 27, 2026

$3.0BEPS $0.22

Q2 2024

Aug 9, 2024

$702MEPS $0.02

Q4 2022

Mar 3, 2023

$610M+13.6%EPS -$0.04

Q3 2022

Nov 7, 2022

$546M+3.2%EPS -$0.02

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$299M	$177M	$92M
Q2 17	$260M	$124M	$45M
Q1 18	$275M	$145M	$64M
Q3 20	$519M	$134M	$2M
Q4 20	$510M	$167M	$20M
Q1 21	$493M	$192M	$46M
Q2 21	$535M	$212M	$67M
Q3 21	$529M	$199M	$29M
Q4 21	$537M	$166M	$11M
Q1 22	$498M	$175M	$23M
Q3 22	$546M	$194M	$44M
Q4 22	$610M	$215M	$36M
Q2 24	$702M	$250M	$95M

Valuation

Quarter	P/S	P/E
Q4 16	—	—
Q2 17	—	—
Q1 18	—	—
Q3 20	2.9x	29.8x
Q4 20	2.5x	51.8x
Q1 21	2.2x	86.3x
Q2 21	1.9x	432.2x
Q3 21	1.9x	285.6x
Q4 21	1.9x	375.4x
Q1 22	1.9x	2263.3x
Q3 22	1.9x	—
Q4 22	1.8x	—
Q2 24	1.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 16	$36M	$5M
Q2 17	$26M	-$4M
Q1 18	$27M	$8M
Q3 20	$45M	$30M
Q4 20	$106M	$75M
Q1 21	$148M	$136M
Q2 21	-$52M	-$60M
Q3 21	$82M	$72M
Q4 21	$63M	$45M
Q1 22	$76M	$66M
Q3 22	$94M	$76M
Q4 22	-$23M	-$35M
Q2 24	$40M	$29M

Capital Expenditures

Quarter	CapEx
Q4 16	$31M
Q2 17	$30M
Q1 18	$19M
Q3 20	$15M
Q4 20	$31M
Q1 21	$12M
Q2 21	$8M
Q3 21	$11M
Q4 21	$18M
Q1 22	$11M
Q3 22	$18M
Q4 22	$11M
Q2 24	$11M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 20	+70.8%	+137.5%
Q1 21	+89.7%	+107.7%
Q2 21	+94.4%	+121.1%
Q3 21	+1.8%	-3.2%
Q4 21	+5.3%	+7.3%
Q1 22	+0.9%	+6.1%
Q3 22	+2.0%	+7.1%
Q4 22	+15.4%	+14.7%
Q2 24	+30.7%	+15.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 16	$0	0.0%
Q2 17	$0	0.0%
Q1 18	$2M	0.6%
Q3 20	$5M	1.0%
Q4 20	$5M	1.0%
Q1 21	$0	0.0%
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q4 21	$8M	1.4%
Q1 22	$0	0.0%
Q3 22	$8M	1.4%
Q4 22	$8M	1.3%
Q2 24	$7M	1.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 16	$44M	—	$31M
Q2 17	$52M	$27M	—
Q1 18	$49M	$25M	—
Q3 20	$47M	—	$83M
Q4 20	$57M	—	$85M
Q1 21	$52M	—	$91M
Q2 21	$54M	—	$86M
Q3 21	$51M	—	$91M
Q4 21	$53M	—	$97M
Q1 22	$54M	—	$99M
Q3 22	$52M	—	$100M
Q4 22	$43M	—	$102M
Q2 24	$37M	—	$116M

Revenue Segments

Quarter	Amneal Specialty Pharma Segment	Av K A R E Segment	Generics Segment
Q3 20	$88M	$90M	$342M
Q1 21	$96M	$85M	$313M
Q2 21	$89M	$86M	$360M
Q3 21	$93M	$89M	$347M
Q1 22	$85M	$95M	$318M
Q3 22	$89M	$106M	$350M
Q4 22	$103M	$108M	$399M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$210M	$2M	$212M
Q2 22	$92M	$2M	$94M
Q3 22	$87M	$2M	$90M
Q4 22	$26M	$2M	$28M
Q1 23	$145M	$3M	$148M
Q2 23	$109M	$3M	$113M
Q3 23	$87M	$5M	$92M
Q4 23	$92M	$2M	$94M
Q1 24	$48M	$0	$48M
Q2 24	$44M	$3M	$47M
Q3 24	$74M	$0	$74M
Q4 24	$111M	$2M	$112M
Q1 25	$59M	$0	$59M
Q2 25	$81M	$0	$81M
Q3 25	$201M	$0	$201M
Q4 25	$311M	$0	$311M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	189M	—	—
Q2 17	115M	-39.2%	—
Q1 18	115M	0.0%	—
Q3 20	148M	+28.5%	—
Q4 20	148M	+0.1%	-21.9%
Q1 21	151M	+2.4%	+31.7%
Q2 21	152M	+0.5%	+32.3%
Q3 21	149M	-1.8%	+1.2%
Q4 21	149M	+0.1%	+1.2%
Q1 22	150M	+0.4%	-0.9%
Q3 22	151M	+1.0%	-0.4%
Q4 22	151M	+0.1%	+1.5%
Q2 24	319M	+110.6%	+113.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	—	—
Q2 17	—	—
Q1 18	—	—
Q3 20	$94.4K	6K
Q4 20	$85.0K	6K
Q1 21	$82.2K	6K
Q2 21	$89.2K	6K
Q3 21	$88.1K	6K
Q4 21	$76.7K	7K
Q1 22	$71.1K	7K
Q3 22	$77.9K	7K
Q4 22	$80.2K	8K
Q2 24	$91.1K	8K

Revenue / Employee